{"id":"bromisoval","rwe":[],"tags":[{"label":"bromisoval","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N05CM03","category":"atc"},{"label":"Active","category":"status"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Hypnotics and Sedatives","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"bromaral","offLabel":[],"synonyms":["bromisovalum","bromaral","bromcarbamide","bromisoval","bromisovalerylurea","bromizoval","bromocarbamide","bromoisovalum","bromovalerocarbamide","bromovaleroylurea","bromovalerylurea"],"timeline":[],"brandName":"Bromaral","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"bromisoval","explanation":"Imagine your brain is a city with many different streets and intersections. Neurotransmitters are like the cars that drive on those streets, carrying messages between different parts of the city. Bromisoval helps keep those cars on the road for longer by blocking the 'garbage trucks' that would normally break them down.","oneSentence":"Bromisoval is thought to work by inhibiting the enzyme responsible for the breakdown of certain neurotransmitters.","technicalDetail":"Bromisoval is a competitive inhibitor of the enzyme responsible for the breakdown of certain neurotransmitters, such as acetylcholine and dopamine, by inhibiting its activity and thereby increasing the concentration and duration of action of these neurotransmitters in the synaptic cleft."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Bromisoval","title":"Bromisoval","extract":"Bromisoval (INN), commonly known as bromovalerylurea, is a hypnotic and sedative of the bromoureide group discovered by Knoll in 1907 and patented in 1909. It is marketed over the counter in Asia under various trade names, usually in combination with nonsteroidal anti-inflammatory drugs."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3038","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=bromisoval","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bromisoval","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Bromisoval","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T09:02:52.427643","biosimilars":[],"competitors":[{"drugName":"scopolamine","drugSlug":"scopolamine","fdaApproval":"1979-12-31","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"propiomazine","drugSlug":"propiomazine","fdaApproval":"1960-12-05","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"triclofos","drugSlug":"triclofos","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ethchlorvynol","drugSlug":"ethchlorvynol","fdaApproval":"1961-05-10","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dexmedetomidine","drugSlug":"dexmedetomidine","fdaApproval":"1999-12-17","patentExpiry":"Jun 26, 2039","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"suvorexant","drugSlug":"suvorexant","fdaApproval":"2014-08-13","patentExpiry":"Nov 20, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lemborexant","drugSlug":"lemborexant","fdaApproval":"2019-12-20","patentExpiry":"Sep 20, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"bromisoval","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"scopolamine","brandName":"scopolamine","genericName":"scopolamine","approvalYear":"1979","relationship":"same-class"},{"drugId":"propiomazine","brandName":"propiomazine","genericName":"propiomazine","approvalYear":"1960","relationship":"same-class"},{"drugId":"triclofos","brandName":"triclofos","genericName":"triclofos","approvalYear":"","relationship":"same-class"},{"drugId":"ethchlorvynol","brandName":"ethchlorvynol","genericName":"ethchlorvynol","approvalYear":"1961","relationship":"same-class"},{"drugId":"dexmedetomidine","brandName":"dexmedetomidine","genericName":"dexmedetomidine","approvalYear":"1999","relationship":"same-class"},{"drugId":"suvorexant","brandName":"suvorexant","genericName":"suvorexant","approvalYear":"2014","relationship":"same-class"},{"drugId":"lemborexant","brandName":"lemborexant","genericName":"lemborexant","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06835660","phase":"NA","title":"DRug-Eluting BallOOn Versus Primary Polymer-coated Paclitaxel Eluting STenting for Femoro-popliteal Lesions","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-05","conditions":["Femoropopliteal Lesion"],"enrollment":402,"completionDate":"2028-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"001436","UNII":"469GW8R486","CHEBI":"CHEBI:31304","INN_ID":"1231","UMLSCUI":"C0006226","ChEMBL_ID":"CHEMBL1515611","KEGG_DRUG":"D01391","DRUGBANK_ID":"DB13370","PUBCHEM_CID":"2447","SNOMEDCT_US":"53845007","MESH_DESCRIPTOR_UI":"D001968"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":30,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05CM03","allCodes":["N05CM03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Bromisoval, also known as Bromaral, is a small molecule drug of the bromisoval class. Its original development is attributed to an unknown entity, and its current ownership is also unclear. The exact target of bromisoval is unknown, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to fully understand the properties and potential uses of bromisoval.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}